

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete If Known	
			Application Number	09/844,544
			Filing Date	April 27, 2001
			First Named Inventor	ZENG, DEFU
			Art Unit	1644
Examiner Name	DIBRINO, MARIANNE			
Sheet 1 of 2	Attorney Docket Number		STAN-190	

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
MD		2002/0009465 AI	January 24, 2002	PORCELLI	
MD		2002/0165170 AI	November 7, 2002	WILSON	
MD		2004/0171522 AI	September 2, 2004	ILAN	
MD		2004/0171557 AI	September 2, 2004	ILAN	

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
MD		WO 00/02583 AI	01/20/2000	NICKOLOFF		
MD		WO 05/014008 A2	02/17/2005	US GOVERNMENT		

NON PATENT LITERATURE DOCUMENTS			
Exam iner Initial	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MD		CHAN et al., Deficiency in α_2 -Microglobulin, But Not CD1, Accelerates Spontaneous Lupus Skin Disease While Inhibiting Nephritis in MRL-Fas ^{lpr} Mice: An Example of Disease Regulation at the Organ Level ¹ , J. Immunol., 167:2985-2990, 2001	
MD		JAHNG et al., Activation of Natural Killer T Cells Potentiates or Prevents Experimental Autoimmune Encephalomyelitis, J. Exp. Med., 194:1789-99, 2001	
MD		LEHUEN et al., Overexpression of Natural Killer T Cells Protects W ^{14-J} 281 Transgenic Nonobese Diabetic Mice against Diabetes, J. Exp. Med. 188:1831-39, 1998	
MD		SHARIF et al., Activation of natural killer T cells by α -galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes, Nature Medicine, 7:1057-62, 2001	

Examiner Signature	/Marianne DiBrino/	Date Considered	07/17/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/844,544	
			Filing Date	April 27, 2001	
			First Named Inventor	ZENG, DEFU	
			Art Unit	1644	
Examiner Name	DIBRINO, MARIANNE				
Sheet	2	of	2	Attorney Docket Number	STAN-190

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MD		SINGH et al., Genetic Deletion of CD1 in Lupus: Evidence of a Regulatory Role, 2001, Arth. Rheum. Suppl., Vol 44, pp 283	
		SWAIN et al., Monoclonal Antibody to L3T4 Blocks the Function of T Cells Specific for Class 2 Major Histocompatibility Complex Antigens, J. Immunol. 132:1118-23, 1984	
		SWAIN S.L., T Cell Subsets and the Recognition of MHC Class, Immunol. Rev., 74:129, 1983	
		WOFSY et al., Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4, J. Exp. Med., 161(2):378-91, 1985	
		YANG et al., Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis, J Immunol., 171(4):2142-53, 2003	
MD		ZENG et al., Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus, J. Clin. Inv. 112:1211-1222, 2003	
		ZENG et al. Subsets of Transgenic T Cells That Recognize CD1 Induce or Prevent Murine Lupus: Role of Cytokines, J. Exp. Med., 187:525-536, 1998	

Examiner Signature	/Marianne DiBrino/	Date Considered	07/17/2006
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.